Given the prior evidence linking the anti‐tumor effects of FABP5‐targeting nanoparticles combined with RFA to ferroptosis induction in HCC, this mechanism was further validated using the ferroptosis inhibitor Lipro1. Here, FABP5 is linked to hepatocellular carcinoma.